Asgard’s immunotherapy, AT-108, induces systemic, dose-dependent efficacy with broad tumor activity in preclinical studies ...

Human immunodeficiency virus-1 (HIV) is one of the most challenging viruses for doctors to treat. Even with effective ...

Kazia Therapeutics expands oncology platform with first-in-class SETDB1 inhibitor drug development platform: Sydney, Australia Wednesday, April 15, 2026, 15:00 Hrs [IST] Kazia The ...

A Survival God for the Age of Abundance,” Peter H. Diamandis and Steven Kotler explore what it means to be human in a world ...

Medical oncologist (ex AstraZeneca, MorphoSys, Autolus Therapeutics) joins to advance Asgard’s lead asset AT-108 into Phase 1 ...

A burgeoning field is launching its first clinical trial to find out whether dialing back cell development can safely refresh ...

Drug development is aiming to move from managing disease to correcting it through RNA and gene-editing therapies. But ...

Plant cells do not easily abandon their mature identity. In apple, that transformation is especially important because somatic embryogenesis underpins ...

Fish oil supplements may not always support brain recovery, as EPA was linked to impaired healing after repeated mild brain injuries. The findings suggest omega-3 effects are context-dependent and not ...

India, April 13 -- Life Biosciences, a clinical-stage biotechnology company focused on reversing diseases of aging, has ...

A single-atom nanozyme mimicking cytochrome c oxidase restores mitochondrial energy production in stem cells, shifting their ...

Scientists are rethinking how to treat a widespread genetic cholesterol disorder by targeting particle production instead of ...